Quantitative CT Perfusion as a prognostic biomarker for chemotherapy response in patients with pancreatic ductal adenocarcinoma

Key Points

• To evaluate the effectiveness of quantitative CT perfusion as a prognostic biomarker for chemotherapy response in pancreatic ductal adenocarcinoma.
• Assess quantitative CT perfusion in patients undergoing chemotherapy for pancreatic ductal adenocarcinoma.
• Compare quantitative CT perfusion results with RECIST criteria for long-term survival identification.
• Quantitative CTP showed better identification of long-term survivors compared to RECIST.
• Increased peak enhancement after chemotherapy was associated with better patient outcomes.